BIIB
Biogen Inc.NASDAQHealthcare$177.34-3.50%ClosedMarket Cap: $26.03B
As of 2026-04-06
Valuation
P/E (TTM)
20.12
PEG
—
P/B
1.38
P/S
2.58
EV/EBITDA
9.43
DCF Value
$736.92
FCF Yield
8.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
70.5%
Operating Margin
19.1%
Net Margin
13.2%
ROE
7.3%
ROA
4.4%
ROIC
6.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $2.28B | 78.2% | $-57.0M | $-48.4M | $-0.33 | — |
| FY 2025 | $9.81B | 70.5% | $1.88B | $1.29B | $8.83 | — |
| Q3 2025 | $2.45B | 64.3% | $613.8M | $466.5M | $3.17 | — |
| Q2 2025 | $2.65B | 64.2% | $588.1M | $634.8M | $4.35 | — |
| Q1 2025 | $2.43B | 76.2% | $732.6M | $240.5M | $1.64 | — |
| Q4 2024 | $2.45B | 76.2% | $509.0M | $266.7M | $1.83 | — |
| FY 2024 | $9.68B | 76.1% | $2.49B | $1.63B | $11.19 | — |
| Q3 2024 | $2.47B | 74.1% | $577.2M | $388.5M | $2.66 | — |
| Q2 2024 | $2.46B | 61.2% | $366.5M | $583.6M | $4.00 | — |
| Q1 2024 | $2.29B | 78.3% | $690.4M | $393.4M | $2.70 | — |
| Q4 2023 | $2.39B | 74.1% | $512.4M | $249.7M | $1.71 | — |
| FY 2023 | $9.84B | 74.2% | $2.10B | $1.16B | $7.97 | — |